



SHUKRA

PHARMACEUTICALS LTD.

12th February, 2021

To
The General Manager-Listing
Corporate Relationship Department
BSE Limited, Ground Floor,
P.J. Towers, Dalal Street, Mumbai.

Scrip Code: 524632

Dear Sir/Madam,

SUB: - OUTCOME OF BOARD MEETING

With reference to above subject and in compliance with the Securities Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby submit the outcome of the Meeting of the Board of Director held on today i.e. 12th February, 2021 at 05.00 p.m. and concluded at 5.30 p.m.:-


1. Considered, adopted and approved Unaudited Financial Results for the quarter ended on 31st December, 2020.

You are requested to kindly take the same on record.

Thanking you,

Yours faithfully

For Shukra Pharmaceuticals Limited


Dakshesh Shah
Managing Director
DIN : 00561666



CIN : L24231GJ1993PLC019079



SHUKRA

PHARMACEUTICALS LTD.

Statement of Standalone unaudited financial results for the Quarter Ended 31.12.2020
Financial results by company

PART I							(Rs. in Lakhs)
Statement of Standalone Unaudited Results for the Quarter Ended 31/12/2020							
Particulars	3 months ended	Preceding 3 months ended	Corresponding 3 months ended in the previous year	Year to date figures for current period ended	Year to date figures for previous period ended	Previous year ended	
	(31/12/2020)	(30/09/2020)	(31/12/2019)	(31/12/2020)	31-12-2019	(31/03/2020)	
(Refer Notes Below)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)	
I Revenue from Operation	414.93	167.60	388.03	693.42	781.02	1184.60	
II Other income	27.01	9.91	0.26	50.87	0.26	0.97	
III Total Revenue (I + II)	441.94	177.51	388.29	744.29	781.28	1185.57	
IV Expenses							
(a) Cost of materials consumed	76.26	7.10	164.68	118.57	307.36	332.82	
(b) Purchase of stock-in-trade	0.00	0.00	0.00	0.00	0.00	0.00	
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	87.11	(24.16)	(38.47)	18.81	(46.51)	(25.90)	
(d) Employee benefits expense	94.38	90.85	134.22	243.25	301.11	440.03	
(e) Finance Cost	0.01	0.30	0.00	0.33	0.07	0.21	
(f) Depreciation and amortisation expense	36.21	36.21	35.05	108.63	85.75	147.82	
(g) Other expenses	118.39	57.99	32.62	214.03	70.77	283.61	
Total expenses	412.36	168.29	328.10	703.62	718.55	1178.59	
V Profit / (Loss) before exceptional and extraordinary items and tax (III - IV)	29.58	9.22	60.19	40.67	62.73	6.98	
VI Exceptional items	0.00	0.00	0.00	0.00	0.00	0.20	
VII Profit / (Loss) before extraordinary items and tax (V - VI)	29.58	9.22	60.19	40.67	62.73	6.78	
VIII Extraordinary items	0.00	0.00	0.00	0.00	0.00	10.30	
IX Profit before tax (VII- VIII)	29.58	9.22	60.19	40.67	62.73	17.08	
X Tax expense - Provision for taxation	8.88	0.00	18.06	12.20	18.82	13.52	
XI Net Profit / (Loss) for the period (IX-X)	20.70	9.22	42.13	28.47	43.91	3.56	
XII Other Comprehensive Income	0.00	0.00	0.00	0.00	0.00	0.00	
Items that will not be reclassified to Profit or Loss: Remeasurement of defined benefits plans (net of tax)							
XIII Total Comprehensive Income) (after tax) for the period (9-10)	20.70	9.22	42.13	28.47	43.91	3.56	

CIN : L24231GJ1993PLC019079



SHUKRA

PHARMACEUTICALS LTD.

XIV	Paid up Equity Share Capital (Face value of Re. 10/- each)	156.57	156.57	156.57	156.57	156.57	156.57
XV	Other Equity excluding revaluation reserve	1421.71	1443.14	1388.07	1421.71	1443.14	1391.73
XVI	Earnings per equity share:						
(1)	Basic	1.32	0.59	2.69	1.82	2.80	0.23
(2)	Diluted	1.32	0.59	2.69	1.82	2.80	0.23

NOTES:

1. The above Results have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at its Meeting held on 12th February , 2021. The statutory auditors have carried out a limited
2. The figures for the previous period/year have been regrouped /reclassified , wherever necessary.
3. This Statement has been prepared in accordance with the Companies (Indian Accounting Standards)
4. The Disclosure is as per Regulation 33 of SEBI (Listing Obligations & Discloser Requirements) Regulations,
5. The Company is operating in single segment, so above results are for single segment only.

Date: 12.02.2021

Place: Ahmedabad

For and on behalf of the Board of Directors

DAKSHESH SHAH
Managing Director
DIN : 00561666

CIN : L24231GJ1993PLC019079



The Limited Review Report

Review Report to Board of Directors Shukra Pharmaceuticals Limited

We have reviewed the accompanying statement of unaudited financial results of Shukra Pharmaceuticals Limited for the quarter ended 31st December, 2020. This statement is responsibilities of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.


We conducted our review in accordance with the Standard on Review Engagement (SRE) 2400, Engagements to Review Financial Statements issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and Analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

**Place: Ahmedabad
Date: 12/02/2021**



**For, B J Trivedi & Associates,
Chartered Accountants
FRN 111042W**


**Bharat Trivedi
Proprietor**

**M. No. 039595
UDIN: 21039595AAAACA1682**